Measurement of the first Townsend ionization coefficient in a methane-based tissue-equivalent gas von Petri, A.R., Gonçalves, J.A.C., Mangiarotti, A., Botelho, S., Bueno, C.C.

Volltext

IMPROVING PATIENT SAFETY THROUGH COMMUNICATION: A BRAZILIAN PERSPECTIVE von Bueno, C.C, Almeida, P.R, Clark, L.G, Clark, O.A

Volltext

Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective von Nishikawa, A.M, Paladini, L, Liamas, A.L, Bueno, C.C, Clark, O.A.C

Volltext

Cost-Effectiveness Analyses of Natalizumab for 2nd Line Versus Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients in Brazil von Nishikawa, A.M, Paladini, L, Liamas, A.L, Bueno, C.C, Clark, O.A.C

Volltext

Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil von Nishikawa, A.M, Paladini, L, Liamas, A.L, Bueno, C.C, Clark, O.A.C

Volltext

Natalizumab for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective von Nishikawa, A.M, Paladini, L, Liamas, A.L, Bueno, C.C, Clark, O.A.C

Volltext

Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil von Nishikawa, A.M, Paladini, L, Liamas, A.L, Bueno, C.C, Clark, O.A.C

Volltext

Burden of Drug Waste in Oncology: Optimization of Resource Use von Castro, A.P, Alves, A.F, Piedade, A, Clark, L.G.O, Bueno, C.C, Minowa, E

Volltext

A Budget Impact Analysis (BIA) of Transcatheter Aortic Valve Implantation (TAVI) in High-Risk Patients with Syntomatic Severe Valve Stenosis (SSVS) Under the Brazilian Public Healt... von Paladini, L, Nishikawa, A.M, Bueno, C.C, Queiroga, M, Lemos, P, Clark, O.A.C

Volltext

An Ethic System Overview: Brazilian Perspectives For Observational Studies von Minowa, E, Bueno, C.C, Piedade, A, Clark, L.G.O, Santinho, C.S, de Castro Monteiro, D.C, Feijo, L.F, Ueda, K, Matos, G.M, Hashimoto, D.A.K

Volltext

PHP165 - IMPROVING PATIENT SAFETY THROUGH COMMUNICATION: A BRAZILIAN PERSPECTIVE von Bueno, C.C., Almeida, P.R., Clark, L.G., Clark, O.A.

Volltext

Rad-Hard Silicon Diode Response for Photon Spectrometry von Goncalves, J.A.C., Camargo, F., Fraga, M.M.R., Pinto, J.K.C., Bueno, C.C.

Volltext

A low-cost small-size commercial PIN photodiode: II. Comparison of measurements with monoenergetic electrons to analytical expressions and Monte Carlo simulations von Mangiarotti, A., Petri, A.R., Malafronte, A.A., Gonçalves, J.A.C., Barros, S.F., Bueno, C.C., Fernández-Varea, J.M., Maidana, N.L., Martins, M.N., Vanin, V.R.

Volltext

A low-cost small-size commercial PIN photodiode: I. Electrical characterisation and low-energy photon spectrometry von Malafronte, A.A., Petri, A.R., Gonçalves, J.A.C., Barros, S.F., Bueno, C.C., Maidana, N.L., Mangiarotti, A., Martins, M.N., Quivy, A.A., Vanin, V.R.

Volltext

The performance of a multi guard ring (MGR) diode for clinical electron beams dosimetry von Nascimento, C.R., Asfora, V.K., Gonçalves, J.A.C., Khoury, H.J., Barros, V.S.M., Kalil, L.F., Bueno, C.C.

Volltext

On the interpretation of current–voltage curves in ionization chambers using the exact solution of the Thomson problem von Ridenti, M.A., Pascholati, P.R., Gonçalves, J.A.C., Bueno, C.C.

Volltext

PND16 - Natalizumab for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Persp... von Nishikawa, A.M., Paladini, L., Liamas, A.L., Bueno, C.C., Clark, O.A.C.

Volltext

PND36 - Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil von Nishikawa, A.M., Paladini, L., Liamas, A.L., Bueno, C.C., Clark, O.A.C.

Volltext

PND3 - Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective von Nishikawa, A.M., Paladini, L., Liamas, A.L., Bueno, C.C., Clark, O.A.C.

Volltext

PND12 - Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients i... von Nishikawa, A.M., Paladini, L., Liamas, A.L., Bueno, C.C., Clark, O.A.C.

Volltext